CanSino Biologics

CanSino Biologics (Chinese: 康希诺生物; pinyin: Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese vaccine company.[1]

CanSino Biologics Inc.
CanSinoBIO
Native name
康希诺生物
Traded as
Founded2009 (2009) in Tianjin, China
Founders
  • Yu Xuefeng
  • Zhu Tao
  • Qiu Dongxu
  • Helen Mao Huihua
Headquarters
Tianjin
,
China
Website

History

CanSino Biologics was founded in 2009 in Tianjin, China by Yu Xuefeng, Zhu Tao, Qiu Dongxu and Helen Mao Huihua.[1]

In July 2018, it filed an application to list on the Hong Kong Stock Exchange.[1] It debuted on 28 March 2019 with an increase of 59%, the highest first day trading gain in Hong Kong since 2017.[2]

Vaccines
See also: COVID-19 vaccine

The company has a portfolio of vaccines under research including Ad5-EBOV to prevent Ebola and Ad5-nCoV for COVID-19. Both are developed jointly with the Institute of Biotechnology of the Academy of Military Medical Sciences of the People's Liberation Army.[1][3]

The company has also collaborated with the National Research Council of Canada on vaccine development. The two organizations began collaborating in 2013, and they later worked together to develop an Ebola vaccine.[4]

In March 2020, CanSino made a deal to collaborate with the NRC on development of the COVID-19 vaccine candidate Ad5-nCoV, to help end the COVID-19 pandemic, with plans to conduct a clinical trial in Canada.[5] Ad5-nCoV was the first COVID-19 vaccine candidate in the world to begin Phase II human trials.[4]

Investors

As of 2018, CanSino Biologics investors included Lilly Asia Ventures, Qiming Venture Partners and SDIC Fund Management.[1]

See also

References
  1. Ng, Eric (25 July 2018). "Chinese vaccine maker CanSino faces tough IPO sell in wake of Changsheng Bio-technology scandal". South China Morning Post. Retrieved 18 April 2020.
  2. Low, Zoe (29 March 2019). "Ebola vaccine maker CanSino Biologics has a plan to take its life-saving treatments well beyond China's domestic market". South China Morning Post. Retrieved 18 April 2020.
  3. Pinghui, Zhuang (10 April 2020). "Volunteers needed for second phase of China coronavirus vaccine trial". South China Morning Post. Beijing. Retrieved 18 April 2020.
  4. Canada, National Research Council. "The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19". www.newswire.ca. Retrieved 19 May 2020.
  5. DeArment, Alaric (13 May 2020). "CanSino Biologics may start clinical development of Covid-19 vaccine in Canada". MedCity News. Retrieved 19 May 2020.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.